Reminder for uniQure N.V. Class Action Participation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy QURE?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. ordinary shares between September 24 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to seek compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the FDA approval status of its pivotal study for Huntington's disease treatment and downplayed the likelihood of delays in its Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information; although no class has been certified yet, participants may choose to retain counsel or remain absent, with future recovery opportunities not contingent on being a lead plaintiff.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 16.940
Low
33.00
Averages
49.88
High
70.00
Current: 16.940
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for uniQure N.V. Class Action Participation
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status for its pivotal study on Huntington's disease, downplayed delays in its Biologics License Application timeline, and as a result, investors suffered losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a securities fraud class action lawsuit due to significant misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with investors able to apply for lead plaintiff status by April 13, 2026.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the clinical trial data for AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, severely undermining investor confidence.
- Legal Action: Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP to discuss their legal rights and explore no-cost recovery options, indicating strong legal support for affected shareholders.
- Uncertain Company Outlook: uniQure admitted that the timeline for its Biologics License Application submission is now unclear, despite plans to urgently interact with the FDA for a path to accelerated approval, which may further erode investor trust and impact future investment decisions.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Disclosure: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure admitted that the timeline for its AMT-130 BLA submission is unclear, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting investor disappointment in the company's prospects.
- False Statement Allegations: The lawsuit alleges that uniQure made materially false statements regarding its clinical trials and FDA application, failing to disclose critical adverse information, which may mislead investors and affect the company's reputation and future financing capabilities.
- Investor Action Recommendation: Affected uniQure investors are advised to apply to be lead plaintiffs in the class action by April 13, 2026, to represent other investors in the litigation, highlighting the legal challenges that may impact the company's long-term strategic development.
See More
Mizuho Upgrades uniQure to Outperform Amid Regulatory Optimism
- Rating Upgrade: Mizuho upgraded uniQure from neutral to outperform, reflecting a significant improvement in the regulatory outlook for Huntington's disease asset AMT-130, with the price target raised from $12 to $35, indicating approximately 107% upside potential.
- Increased Regulatory Flexibility: Analyst Uy Ear noted that the departure of FDA official Vinay Prasad may signal an administrative desire to restore greater regulatory flexibility in rare disease development, which is seen as a positive signal for uniQure, potentially reopening a path to a BLA based on existing Phase 1/2 data or a Phase 3 trial using natural history controls.
- Success Probability Boost: The analyst raised the probability of success for AMT-130 from 15% to 55%, indicating increased confidence in the product's future development, while also advancing the potential launch date to 2028 from 2030, marking significant progress.
- Positive Market Reaction: Following the departure of a key FDA official, biotech stocks generally rose, with uniQure's stock experiencing a substantial increase, reflecting market optimism regarding its future prospects.
See More
uniQure Faces Unprecedented Federal Criticism Amid Class Action Investigation
- Federal Officials' Rebuke: On March 5, 2026, The Wall Street Journal reported that federal health officials publicly criticized uniQure N.V.'s lead gene therapy candidate AMT-130, stating that the company provided flawed clinical data, which significantly undermined FDA approval confidence and directly impacted investor sentiment and stock price.
- Stock Price Plunge: Since November 3, 2025, uniQure's stock has fallen nearly 84%, reflecting a drastic market reaction to the company's deteriorating outlook, particularly in light of the FDA's criticisms, resulting in substantial investor losses.
- Class Action Lawsuit Initiated: A securities class action lawsuit has been filed for the period between September 24, 2025, and October 31, 2025, encouraging investors to contact Hagens Berman for potential compensation, indicating further reputational damage for the company amid legal scrutiny.
- Dispute with FDA: FDA officials accused uniQure of misleading statements in their communications, leading to a loss of trust in the clinical trial data, which not only affects the approval timeline for AMT-130 but could also have long-term implications for the company's strategic direction.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that they must file lead plaintiff applications by April 13, 2026, to participate in the securities class action lawsuit concerning stock transactions between September 24 and October 31, 2025, highlighting investor concerns over company transparency.
- Disclosure Failures: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the anticipated FDA accelerated approval for its leading drug candidate AMT-130, leading to diminished investor confidence.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA's timeline for AMT-130's BLA submission was unclear, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, reflecting a pessimistic outlook on the company's future.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service to assist investors in understanding their legal options and connecting with Kahn Swick & Foti, LLC law firm, demonstrating a commitment to supporting investor rights.
See More
Reminder for uniQure N.V. Class Action Participation
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status for its pivotal study on Huntington's disease, downplayed delays in its Biologics License Application timeline, and as a result, investors suffered losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a securities fraud class action lawsuit due to significant misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with investors able to apply for lead plaintiff status by April 13, 2026.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the clinical trial data for AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, severely undermining investor confidence.
- Legal Action: Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP to discuss their legal rights and explore no-cost recovery options, indicating strong legal support for affected shareholders.
- Uncertain Company Outlook: uniQure admitted that the timeline for its Biologics License Application submission is now unclear, despite plans to urgently interact with the FDA for a path to accelerated approval, which may further erode investor trust and impact future investment decisions.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Disclosure: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure admitted that the timeline for its AMT-130 BLA submission is unclear, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting investor disappointment in the company's prospects.
- False Statement Allegations: The lawsuit alleges that uniQure made materially false statements regarding its clinical trials and FDA application, failing to disclose critical adverse information, which may mislead investors and affect the company's reputation and future financing capabilities.
- Investor Action Recommendation: Affected uniQure investors are advised to apply to be lead plaintiffs in the class action by April 13, 2026, to represent other investors in the litigation, highlighting the legal challenges that may impact the company's long-term strategic development.
See More
Mizuho Upgrades uniQure to Outperform Amid Regulatory Optimism
- Rating Upgrade: Mizuho upgraded uniQure from neutral to outperform, reflecting a significant improvement in the regulatory outlook for Huntington's disease asset AMT-130, with the price target raised from $12 to $35, indicating approximately 107% upside potential.
- Increased Regulatory Flexibility: Analyst Uy Ear noted that the departure of FDA official Vinay Prasad may signal an administrative desire to restore greater regulatory flexibility in rare disease development, which is seen as a positive signal for uniQure, potentially reopening a path to a BLA based on existing Phase 1/2 data or a Phase 3 trial using natural history controls.
- Success Probability Boost: The analyst raised the probability of success for AMT-130 from 15% to 55%, indicating increased confidence in the product's future development, while also advancing the potential launch date to 2028 from 2030, marking significant progress.
- Positive Market Reaction: Following the departure of a key FDA official, biotech stocks generally rose, with uniQure's stock experiencing a substantial increase, reflecting market optimism regarding its future prospects.
See More
uniQure Faces Unprecedented Federal Criticism Amid Class Action Investigation
- Federal Officials' Rebuke: On March 5, 2026, The Wall Street Journal reported that federal health officials publicly criticized uniQure N.V.'s lead gene therapy candidate AMT-130, stating that the company provided flawed clinical data, which significantly undermined FDA approval confidence and directly impacted investor sentiment and stock price.
- Stock Price Plunge: Since November 3, 2025, uniQure's stock has fallen nearly 84%, reflecting a drastic market reaction to the company's deteriorating outlook, particularly in light of the FDA's criticisms, resulting in substantial investor losses.
- Class Action Lawsuit Initiated: A securities class action lawsuit has been filed for the period between September 24, 2025, and October 31, 2025, encouraging investors to contact Hagens Berman for potential compensation, indicating further reputational damage for the company amid legal scrutiny.
- Dispute with FDA: FDA officials accused uniQure of misleading statements in their communications, leading to a loss of trust in the clinical trial data, which not only affects the approval timeline for AMT-130 but could also have long-term implications for the company's strategic direction.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that they must file lead plaintiff applications by April 13, 2026, to participate in the securities class action lawsuit concerning stock transactions between September 24 and October 31, 2025, highlighting investor concerns over company transparency.
- Disclosure Failures: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the anticipated FDA accelerated approval for its leading drug candidate AMT-130, leading to diminished investor confidence.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA's timeline for AMT-130's BLA submission was unclear, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, reflecting a pessimistic outlook on the company's future.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service to assist investors in understanding their legal options and connecting with Kahn Swick & Foti, LLC law firm, demonstrating a commitment to supporting investor rights.
See More
